Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 65.33 |
| Open | 65.53 |
| Bid | 64.76 x 200 |
| Ask | 64.80 x 200 |
| Day's Range | 64.33 - 65.53 |
| 52 Week Range | 64.33 - 87.87 |
| Volume | |
| Avg. Volume | 7,395,591 |
| Market Cap | 80.779B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 179.94 |
| EPS (TTM) | 0.36 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 3.08 (4.75%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | 76.33 |
ACCESSWIREForbes Has Listed Gilead as One of America’s Best Employers for Diversity
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking ...
ZacksThe Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
- Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
© 2024 Yahoo. All rights reserved.